Testing new drug combinations for pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pleural mesothelioma (a type of cancer that affects the lining of the lungs) through a biopsy.
- Your cancer cannot be surgically removed and has been confirmed by a specialist team.
- You have not had chemotherapy or immunotherapy for this cancer before.
- You are between 18 and 75 years old.
- You have good kidney and liver function, and your blood counts are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
Hear when a new Pleural Mesotheliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.